ABSTRACT G-protein coupled receptor kinase 2 (GRK2) regulates the activity of many receptors. Because potent inhibitors of GRK2 are thus far limited to polyanionic compounds like heparin, we searched for new inhibitors with the aid of a molecular model of GRK2. We used the available crystal structure of cAMP dependent protein kinase (cAPK) as a template to construct a 3D homology model of GRK2. Known cAPK and GRK2 inhibitors were docked into the active sites of GRK2 and cAPK using DOCK v3.5. H8 docked into the hydrophobic pocket of the adenosine 5'-triphosphate (ATP) binding site of cAPK, consistent with its known competitive cAPK inhibition relative to ATP. Similarly, 3 of 4 known GRK2 inhibitors docked into the ATP binding pocket of GRK2 with good scores. Screening the Fine Chemicals Directory (FCD, containing the 3D structures of 13,000 compounds) for docking into the active sites of GRK2 identified H8 and the known GRK2 inhibitor trifluoperazine as candidates. Whereas H8 indeed inhibited light-dependent phosphorylation of rhodopsin by GRK2, but with low potency, 3 additional FCD compounds with promising GRK2 scores failed to inhibit GRK2. This result demonstrates limitations of the GRK2 model in predicting activity among diverse chemical structures. Docking suramin, an inhibitor of protein kinase C (not present in FCD) yielded a good fit into the ATP binding site of GRK2 over cAPK. Suramin did inhibit GRK2 with IC50 32 μM (pA 2 6.39 for competitive inhibition of ATP). Suramin congeners with fewer sulfonic acid residues (NF062, NF503 [IC50 14 μM]) or representing half of the suramin molecule (NF520) also inhibited GRK2 as predicted by docking. In conclusion, suramin and analogues are lead compounds in the development of more potent and selective inhibitors of GRK2.
INTRODUCTION
G-protein coupled receptors (GPCRs) play an important role in signal transduction across the cell membrane. Upon agonist stimulation, GPCR activity is generally regulated by receptor phosphorylation 1 , mediated mainly by 2 classes of kinases, ie, second messenger kinases (cAMP dependent protein kinase [cAPK] , cGMP dependent protein kinase, protein kinase C, and Ca 2+ /calmodulin dependent protein kinases) 2 , and G-protein coupled receptor kinases (GRKs). The latter phosphorylate GPCRs only if the receptor is in an active or stimulated conformation 3 . Meanwhile, at least 7 GRK subtypes have been cloned 4, 5 of which GRK2 (synonymous with ARK1, -adrenergic receptor kinase 1) is extensively expressed in the central nervous system. GRK2 phosphorylates a variety of neurotransmitter receptors, including the 2 adrenergic receptor 6 . Further known substrates of GRK2 are the 2 adrenergic receptor 7 , muscarinic acetylcholine receptors 8, 9 , the d-opioid receptor 10 , and rhodopsin, even though the latter is physiologically regulated by GRK1 11 .
The pervasive role of GRK2 in GPCR regulation prompted us to initiate a search for selective inhibitors. So far, the polyanions, heparin and dextrane sulfate, are the most potent inhibitors (IC50 0.15 μM) 12 . However, they do not readily cross the cell membrane. In order to study the physiological impact of GRK2 on the regulation of GPCRs, a cell-permeable inhibitor would be useful. Knowledge of the 3D structure of the enzyme can be useful in the design of potent and selective inhibitors. The docking of compounds in large chemical databases into a molecular model of a target protein using the DOCK software package developed by Kuntz and collegues [16] [17] [18] [19] has proven valuable as a screening procedure, providing insight into ligand-receptor interactions and suggesting possible lead compounds 20 . However, the crystal structure of GRK2 has yet to be reported. A large number of kinases share a highly conserved catalytic core, and the crystal structure of several kinases has already been reported. For example, the crystal *Corresponding author: Matthias U. Kassack, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121;Telephone: +49-228-735240, Facsimile: +49-228-737929, E-mail: kassack@uni-bonn.de 1 AAPS PharmSci 2000; 2 (1) article 2 (http://www.aapspharmsci.org). structure of the catalytic subunit of cAMP dependent protein kinase (cAPK) complexed with Mg adenosine 5'-triphosphate (ATP) and a peptide inhibitor has been resolved 13, 14 . On the basis of high sequence identity between cAPK and the catalytic core of GRK2, we employed here the cAPK structure as a template for homology modeling of GRK2 in a fashion similar to that of Iino and Shibano 15 . Whereas Iino and Shibano applied their model to identify substrate recognition mechanisms of GRK2, we used our homology model as a means to better understand the molecular architecture of the active site and to guide the design of kinase inhibitors.
First, we compared the docking properties of known GRK2 and cAPK inhibitors using the molecular models of both enzymes. The molecular model of cAPK and the homology model of GRK2 served as screens for the best-fitting structures in a chemical databank (Fine Chemicals Directory). Subsequently, compounds identified with favorable docking parameters were also tested for their ability to inhibit GRK2 in a biochemical assay using rhodopsin phosphorylation 12 . We then tested known general inhibitors of protein kinases biochemically and by docking. The PKC inhibitor suramin selectively docked to and inhibited GRK2 over cAPK. This result prompted us to screen analogues of suramin, resulting in new lead compounds.
MATERIALS AND METHODS

Sequence Alignment of cAPK and GRK2 and Homology Modeling
The sequences of the catalytic subunit of cAPK (2CPKE.1, 350 amino acids) and GRK2 (ARK1_HUMAN, 689 amino acids) were aligned by a system of neural networks available by a mail server service (EMBL, Heidelberg, Germany, http://www.emblheidelberg.de/Services/index.html) [21] [22] [23] . The alignment program does not insert gaps within predicted secondary structure elements (335 amino acids were aligned). Seven gaps were introduced into the sequence of cAPK. The atomic coordinates of the crystal structure of the catalytic subunit of cAPK complexed with MgATP and a peptide inhibitor were retrieved from the Brookhaven Protein Data Bank (2cpk, http://www.rcsb.org/pdb) 24 . The model of cAPK consists of catalytic residues 15 to 350 13 .
For the construction of the GRK2 model, the 335 aligned amino acids were used. The gaps in the sequence of cAPK were not filled with the amino acid sequence of GRK2. The atomic coordinates of the amino acids in cAPK were applied to the corresponding amino acids in GRK2 using MIDAS Plus software 25 (available from http://www.sacs.ucsf.edu). The resulting model was energy minimized to convergence with Sybyl (Tripos Associates, St. Louis, MO) using a 3-stage protocol involving simplex, conjugate-gradient, and Powell minimization methods 26 . Calculations were performed on Silicon Graphics IRIS 4D/25 workstations (for further information see http://www.sgi.com/).
Docking of Potential Inhibitors of GRK2
Docking of potential inhibitors of GRK2 and cAPK was performed using the DOCK 3.5 software package [16] [17] [18] [19] . Briefly, a molecular surface of the target site was created using the MS algorithm 27 . The target site on the GRK2 and cAPK models was chosen based on the contact region of cAPK and its protein inhibitor 14, 28 . The program SPHGEN 16 (available at http://www.sacs.ucsf.edu/) was used to create a negative image of the receptor site by filling the target region with overlapping spheres of varying sizes. The CHEMGRID program 18 (available at http://www.sacs.ucsf.edu/) generates grids for force-field interaction evaluation and was run using a grid resolution of 0.3 Å, a distance-dependent dielectric constant of 4r (where r is the interatomic separation), a nonbonded cutoff of 10 Å, and lose contact limits of 2.3 and 2.8 Å, respectively, for polar and nonpolar atoms. Hydrogens were added to the receptor in standard geometries. ) was clustered by shape similarity using the method of Bemis and Kuntz 30 . The resulting database of 13,028 commercially available compounds was screened against GRK2 and cAPK with DOCK v3.5 using force-field score optimization with interpolation 19 . Two unfavorable contacts were tolerated in the docking, dislim was set to 1.5, ligand bin size and overlap were set to 0.1 and 0.1, and receptor bin size and overlap were set to 0.3 and 0.1; an average of 1,700 configurations were thus analyzed for each putative ligand.
Conformational Analysis and Docking of Known GRK2 and cAPK Inhibitors
Compounds were energy-minimized without electrostatics to convergence in Sybyl 26 . Conformations for each compound were generated using Sybyl's systematic search feature, retaining structures within 5 kcal/mol of the lowest energy conformation. Surviving conformations were docked to both GRK2 and cAPK using identical docking parameters as above.
Materials
-[
33 P]-Adenosine triphosphate was purchased from DuPont NEN. Bovine cDNA of GRK2 ( -adrenergic receptor kinase 1) and a dominant-negative mutant of GRK2 (GRK2-K220W) were obtained from Dr. T. Haga (pEF-GRK2, pEF-GRK2-K220W) 31 . Bovine GRK2 shares 98% identity with human GRK2. The compounds Cell Culture and Transfection of pEF-GRK2 and pEF-GRK2-K220W, a Dominant Negative Mutant
Human embryonic kidney cells (HEK293) were grown in Dulbecco's minimal essential medium (F12 50/50%) supplemented with 10% inactivated fetal calf serum at 37°C in 95% air and 5% CO 2 . Twenty four hours prior to transfection, HEK293 cells were plated on 10-cm dishes (10 6 cells/dish). Cells were transiently transfected with 10 μg of pEF-GRK2 or pEF-GRK2-K220W per 10 cm dish using the calcium phosphate transfection method. After 48 hours, cells were scraped into 200-μl ice-cold lysis buffer per 10-cm dish (25 mM Tris-HCl pH 7.5, 5 mM EDTA, 0.1 mM phenylmethylsulfonylfluoride, 5 μg/mL pepstatin, 10 μg/mL leupeptin, and 10 μg/mL benzamidine). Cells were lysed using a dounce homogenizer (15 strokes), followed by centrifugation at 50,000g for 1 hour. The supernatant was used as source for GRK2 or dominant negative GRK2. Untransfected HEK293 cells were used as the control.
Detection of GRK2 Activity and Testing of Potential Inhibitors of GRK2
Rhodopsin served as substrate for GRK2. The preparation of urea-treated bovine rod outer segments (ROS) was performed as previously described 32 under dim red light. Urea-treated ROS showed no endogenous kinase activity, and rhodopsin accounted for the majority of proteins present, as assessed by Coomassie Blue staining of polyacrylamide gels.
Phosphorylation reactions employed urea-treated ROS (~200 pmol rhodopsin) and 10 μl supernatant of lysed transiently transfected HEK293 cells (or alternatively, 0.5 μl of GRK2 [2 μM, purified from Sf9 cells provided by Dr. T. Haga]) in 20 mM Tris HCl pH 7.5, 2 mM EDTA, 5 mM MgCl 2 , and 100 μM -[
33 P]-ATP (4440 cpm/fmol), prepared under red light and kept in the dark. Incubations were at 33°C in the presence of white light for 30 minutes, and were stopped by the addition of 1 mL ice-cold 100 mM sodium phosphate/5 mM EDTA buffer at pH 7.5. After centrifugation at 12,000g for 5 minutes, the pellet was resuspended in 30 μl SDS loading buffer (2% sodium dodecyl sulfate, 10% glycerol, 0.1 M dithiothreitol, 0.001% bromophenolblue in 0.08 M Tris HCl pH 6.8) and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 10% homogenous polyacrylamide gel. After autoradiography, films were scanned using an Intas Imaging System (available from http://www.sacs.ucsf.edu/). Quantitative data were obtained with Gelscan 3D v2.1 (Marburg, Germany). To test potential inhibitors of GRK2, the compounds were added to the phosphorylation mixture at a final concentration of 100 μM unless otherwise stated. IC50 values were calculated using GraphPad Prizm Software v2.01.
RESULTS
Homology Model of GRK2 Based on cAPK
The sequence alignment of GRK2 with the catalytic subunit of cAPK (amino acids 15 to 350) yielded a residue identity of 31%. The aligned amino acids of GRK2 comprise residues 163 to 524, representing the catalytic domain of GRK2 (Figure 1) . The amino-and carboxytermini of GRK2 show no significant homology with cAPK 6 and were omitted from the GRK2 model. Several small gaps in the alignment of GRK2 with cAPK were located within exterior loops of the resolved cAPK structure, suggesting that their omission would not lead to serious distortion of the overall tertiary structure of GRK2. Thus, a total of 335 amino acids were used for the construction of the GRK2 model. In cAPK, the adenine ring of ATP is anchored in a hydrophobic pocket with 2 additional H-bonds. The segment Met120 through Val123 plays a role in the recognition and anchoring of the adenine ring by hydrophobic interaction and hydrogen bonding, and it is the linker region between the small and large lobes 14 . The relevant amino acids are listed in Table 1a , along with the aligned amino acids of GRK2. Where residues differ between cAPK and GRK2, substitutions are conservative and can contribute to the hydrophobicity of the pocket or are capable of hydrogen bonding with the N6 amino group and N7 nitrogen of the adenine ring (Asp121 and Ser183 in GRK2). Similarly, the Glu127 residue in cAPK interacting with the 2'-hydroxy group of the ATP ribose ring 14 is substituted with an Asp residue in GRK2 ( Table  1b) . The invariant Lys72 residue present in all protein kinase catalytic domains, including GRK2, appears to be involved in the phospho-transfer reaction rather than in anchoring of ATP 33 . Glu91, also conserved in GRK2, stabilizes the anchoring of the -and -phosphates of ATP. The -phosphate is further anchored by the backbone amides of the glycine-rich loop, which is highly conserved in GRK2 (Table 1c) .
The catalytic loop is the most conserved region (Table  1d , and Figure 2A [static image]). All amino acids except one (Glu170, cAPK Ala, GRK2) are invariant in cAPK and GRK2. Lys168, conserved in all Ser/Thr kinases, binds to the -phosphate, as demonstrated for cAPK complexed with an inhibitor 14 . In cAPK, the side chain of the invariant Asp166 is close to the serine/threonine of a substrate. One of the 2 magnesium ions in the cAPK crystal structure is coordinated by the oxygens of the -and -phosphate of ATP and by the invariant Asp184. The second magnesium ion coordinates with the -and -phosphates and the invariant Asn171. Thus, only 2 invariant residues from the large lobe contribute to the binding of the phosphates of ATP: Asn171 and Asp184. Mainly, the nucleotide binding motif is contained in the small lobe (glycine rich loop, Lys72, Glu91).
Docking of Compounds Into GRK2
Docking ATP into the GRK2 model yielded the expected good score (the more negative the value, the better the fit) with a fit close to the proposed ATP binding pocket (Table 2B and Figure 2B [static image]), indicating that the model is adequate for identifying the predicted ATP site. Minor deviations from the expected orientation may be the result of ommitting the Mg 2+ ions associated with ATP in the active site because they could not be readily incorporated into the docking procedure. To identify a putative binding site for inhibitors, we first docked the kinase inhibitor H8 into the model of cAPK and GRK2 (Figure 2A [static image] ). Although H8 is a known and relatively selective cAPK inhibitor 34 , its activity against GRK2 was unknown. In cAPK, the isoquinoline ring of H8 is preferentially docked into the hydrophobic binding pocket for the adenine ring of ATP (Figure 2A left [static image] ), thereby possibly accounting for the competitive (with respect to ATP) inhibitory effect of H8 on cAPK 34 . For GRK2, H8 docked into the same pocket but with a slightly different rotation, yielding a slightly lower docking score than with cAPK ( Table 2) . H8 is indeed a weak inhibitor of GRK2 ( Table 2) suggesting the hydrophobic ATP binding pocket as a putative target for GRK2 inhibitors. To test this hypothesis further, several known GRK2 inhibitors with published IC50 values 12 were also docked into the GRK2 and cAPK models. Although none of these known inhibitors were highly potent or selective (Table 2A) , they docked into or close to the ATP binding pocket, except pyridoxal phosphate and tamoxifen, for which the binding pocket in GRK2 was less well defined. The docking scores and the inhibitory potency of the known GRK2 inhibitors did not correlate (Table 2A) . Nevertheless, because most known inhibitors docked into the hydrophobic ATP binding pocket, these results support the potential relevance of this pocket as a putative target in the search of new inhibitors.
Subsequently, we screened a database containing 13,028 defined structures (FCD) by docking each into the GRK2 model. For the first screen, 1,000 structures were selected on the basis of their docking scores for GRK2. The same compounds were also docked into the molecular model of cAPK. To reduce the number of potential inhibitors identified by the docking screen, additional selection criteria included similar or superior scores for GRK2 over cAPK, in order to identify GRK2-selective inhibitors. Only compounds that scored well and had a favorable fit into the central cleft of GRK2, close to the hydrophobic ATP binding pocket, were selected and subsequently tested as inhibitors of GRK2. Table 2 shows the docking scores of these selected compounds for GRK2 and cAPK. Only H8 showed a slightly better score for cAPK than GRK2, but it was nevertheless tested further because it is a known cAPK inhibitor with unknown activity towards GRK2.
In general, docking of polyanionic compounds is expected to be biased toward more negative scores in the docking procedure used and were therefore excluded in most cases. Inositol-1, 4-bisphosphate (IP2) was among the highest scoring and selective compounds for GRK2 in the screened chemical database. Even though IP2 is highly charged, inositol phosphates were tested further because they are important second messengers of GPCR signaling and may play a role in receptor regulation. Inositol-1-monophosphate (IP) and inositol-1, 4, 5-triphosphate (IP3), not contained in the database, were also modeled and docked, yielding excellent scores as well, with selectivity for GRK2 over cAPK ( Table 2) . These inositol phosphates were included because of their biological relevance, whereas the excellent GRK2 scores were suspected to be biased.
Last, we docked the general inhibitor suramin into the model of GRK2. Suramin gave an excellent score, with selectivity for GRK2 over cAPK and a good fit into the central cleft of GRK2 (Figure 2C [static image] ). Sura Table 2 . GRK2 and cAPK docking scores for selected compounds with a good fit into the central cleft of the GRK2 model and cAPK. The more negative values indicate the better score. Also provided are the IC50 values for inhibiting GRK2, determined in this study or elsewhere (12) , and published IC50 values for cAPK where available. Compounds are divided into groups according to the indicated criteria. min is also charged, but it contains a large lipophilic central section that is likely to play a role in the docking scores. Moreover, the purine analogue IBMX(1-isobutyl-3-methyl xanthine) was docked as a suspected kinase inhibitor, but it gave a rather poor score at both cAPK and GRK2.
Biochemical Evaluation of Potential Inhibitors of GRK2
The GRK2 assay is based on phosphorylation of the photoreceptor rhodopsin by GRK2 11 . Figure 3 shows the 33 P-labeled band of rhodopsin at ~30 kd (and of rhodopsin oligomers at higher molecular weight) in a typical phosphorylation assay, using the cytosolic fraction of HEK293 cells transfected with GRK2 constructs as an enzyme source. The phosphorylation of rhodopsin was light-dependent, as can be seen from the GRK2 controls determined under dark or light conditions (lanes 1 and 2). Similar results were obtained with GRK2 purified from Sf9 cells using a baculovirus expression system 9 (data not shown). Addition of the transfected dominant negative mutant of GRK2 (GRK2-K220W, using the same plasmid construct) failed to enhance labeling of the light-activated rhodopsin band at ~30 kd (lane 4), relative to GRK2 wild-type, showing that transfected GRK2 kinase activity was required. Supernatants taken from untransfected HEK293 cells show little GRK2-like activity (lane 3). The rhodopsin preparation itself contained no endogenous kinase activity (data not shown). These control experiments demonstrate that the rhodopsin assay using supernatants of HEK293 cells transfected with GRK2 indeed measured GRK2 activity, rather than other kinase activities. As expected, the known GRK2 inhibitor heparin inhibited GRK2 by 90% at 1 μM (Figure 4) .
Several compounds are known inhibitors of GRK2, but these are neither highly selective nor potent. Their published IC50 values for inhibiting GRK2 12 are listed in Table 2 , in comparison to their docking scores for GRK2 and cAPK. Trifluoperazine, chlorpromazine, and sangivamycine displayed intermediate activity as GRK2 inhibitors, paralleling their intermediate scores obtained from docking into the ATP binding pocket. Compound H7 is considerably more potent in inhibiting cAPK than GRK2, paralleling its docking scores against GRK2 (-32.0) and cAPK (-36.4) ( Table 2C ). The rather low potency of pyridoxal phosphate relative to its excellent docking score likely resulted from overestimation of the score because of the charged phosphate moiety. On the 2000; 2 (1) article 2 (http://www.aapspharmsci.org) .
AAPS PharmSci
In contrast to trifluoperazine and H8 (weak GRK2 inhibitor), coralyne, bicucullin, and nikkomycin did not measurably inhibit GRK2 when added at 100 μM (Figure 3 and Figure 4 ), even though they docked well into the central cleft of GRK2. Thus, searching the chemical library for inhibitors on the basis of the GRK2/cAPK resulted in several false positives, and we were unable to find a novel structure by this approach. Furthermore, none of the inositol phosphates (IP, IP2, IP3) showed any inhibition of GRK2 even at 1 mM (data not shown).
As expected, the scores for these charged molecules were biased. IBMX (1-isobutyl-3-methylxanthine), a known phosphodiesterase inhibitor and purine analogue, scored poorly against GRK2, and it was also tested for GRK2 inhibition ( Table 2) . Moreover, IBMX was included in this study because we had reported earlier that it inhibits a basal phosphorylation reaction of the μ-opioid receptor at 10 μM 35 . If GRK2 were involved in this phosphorylation reaction, we would have expected IBMX to inhibit GRK2 activity in our biochemical assay. However, IBMX failed to inhibit rhodopsin phosphorylation by GRK2 at 100 μM (Figure 4) , and even at 250 μM, no inhibition of GRK2 occurred (data not shown). This finding suggests that a kinase other than GRK2 is likely to mediate the previously reported basal phosphorylation of the μ-opioid receptor 35 . Also, the poor docking score of IBMX is consistent with its failure to inhibit GRK2.
Several potential kinase inhibitors (not in the condensed FCD used) of unknown activity against GRK2 but with known inhibitory activity against other kinases were selected to test their ability to inhibit GRK2. The cAPK inhibitor H8 was found to inhibit GRK2 by 40% at 100 μM (Figure 4) . When compared with H7 (IC50 = 250 μM) 12 , H8 was only slightly more potent (IC50: 100-200 μM) reflecting their almost identical scores against GRK2. Because of its rather low potency, the IC50 value of H8 was not determined more precisely. The cAPK score of H8 is only slightly better than its GRK2 score, but H8 is a considerably more potent inhibitor of cAPK than of GRK2 ( Table 2) . Therefore, the GRK2 and cAPK scores did not correspond well with measured inhibitory potencies of H7 and H8. other hand, tamoxifen was relatively more potent while attaining a lesser docking score. This is probably related to the failure of this inhibitor to dock into the adenine binding pocket of GRK2. Although most known inhibitors docked into the ATP binding pocket with reasonable scores, there is no clear quantitative correlation between the GRK2 score and potency among compounds with different chemical structures.
Suramin, a known inhibitor of several different enzymes, including protein kinase C and (very weakly) cAPK 36 , was also docked into our GRK2 homology model. Suramin occupies the entire length of the central cleft of GRK2 (Figure 2C [static image]) and attained a high docking score, with strong preference for GRK2 over cAPK ( Table 2) . Moreover, in our GRK2-rhodopsin assay, suramin was one of the most potent inhibitors among the tested compounds, with an IC50 of 32 ± 7 μM (Table 2, Figure 4) . Suramin was shown to inhibit GRK2 in a competitive manner in regard to ATP. Figure 5 shows the parallel right shift of the dose-response curve of ATP with increasing concentrations of suramin. Schild
We then tested several compounds identified by the docking screen of the chemical library. Compounds were selected if they showed an acceptable GRK2 score (<-30) similar to or in preference over cAPK and a good fit into the adenine binding pocket of GRK2. Among the selected compounds were trifluoperazine (previously shown to inhibit GRK2 with an IC50 of 35 μM 12 [ Table  2A ]), coralyne chloride, bicuculline methobromide, nikkomycin Z, and H8. Polyphosphates were excluded from the study because of their polyanionic structure, except for the inositol phosphates. analysis yielded a linear regression, with a slope of 1.1 ± 0.1 and a pA 2 value of 6.39 ± 0.05.
Because the docking of suramin into our GRK2 homology model suggests that only a portion of the suramin molecule is bound into the central cleft of GRK2 ( Figure  2C [static image]), we tested the precursor half-molecule NF520 for inhibition of GRK2 ( Table 3) . It indeed inhibited GRK2, but only at a high concentration (IC50 = 792 μM) ( Table 3) . Furthermore, we screened the suramin analogues NF062 and NF503 bearing only 2 instead of 6 sulfonic acid residues. Both compounds inhibited GRK2, with slightly lower IC50 values than suramin (Table 3) . Thus, suramin analogues displayed inhibitory affinities in the low μM range 2000; 2 (1) article 2 (http://www.aapspharmsci.org) .
DISCUSSION
GRK2 plays an important role in the regulation of different G protein-coupled receptors 5 ). So far, only polyanionic compounds like heparin are known potent inhibitors of GRK2. This prompted us to search for alternative potent and selective inhibitors of GRK2. The use of molecular modeling and docking of small compounds into the target sites of molecular models derived directly from resolved crystal structures has already proven valuable for discovering new ligands 20 . Moreover, this approach has also been successful for molecular models based on homology to a protein of known structure 38 . Our strategy was to construct a model of GRK2 based on high homology to the sequence of a kinase of known crystal structure, cAPK. Subsequently, we tested the homology model by docking ATP and already known inhibitors into the active site of GRK2 and its utility in screening and design of new inhibitors.
GRK2 is a homolog of cAPK, showing a high degree of identity in the nucleotide binding region and the catalytic loop ( Table 1) . The nucleotide binding domain holds ATP on one side of the cleft, whereas the catalytic loop embraces ATP from the other side. As found throughout the protein kinase family, residues Lys72, Glu91, Lys168, and Asp184 of cAPK are also invariant in GRK2 37 suggesting the same or a similar function for these residues in all kinases. This finding justified building a molecular model of GRK2 based on homology.
Because of the high homology in the nucleotide binding region and the catalytic loop between GRK2 and cAPK, the homology model of GRK2 retained a hydrophobic pocket within the central cleft accommodating the adenine ring of ATP (Table 1, Figure 2B [static image]) as well as being the preferred docking site for a number of test structures, eg, H8 (Figure 2A [static image] ). As would be expected, ATP yielded a high score by fitting close to its predicted pocket. Subsequently, we docked known GRK2 inhibitors into the central cleft of the enzyme. Trifluoperazine, H7, chlorpromazine, and sangivamycine docked into the ATP binding pocket ( Table 2) . Although pyridoxal phosphate scores better than trifluoperazine, its IC50 is ~30-fold higher than that of trifluoperazine. A reason for this difference may be that pyridoxal phosphate does not show a preference for a particular pocket but that because of its anionic character it scores rather well. Electrostatic-ionic interactions are overestimated in the calculation of the docking scores because dehydration energies are not considered 20 . Tamoxifen, too, does not show a strong preference for a particular binding pocket and attains a poor score, yet it inhibits GRK2 with an IC50 of 40 μM. These results show that the homology model of GRK2 is able to identify the ATP binding pocket and to account for the inhibition of most of the docked known inhibitors of GRK2. Nevertheless, a quantitative correlation between the docking score and the inhibitory potency among diverse chemical structures could not be detected, and not all known inhibitors scored well. Currently, there are no GRK2 inhibitors of high potency available that fit tightly into the binding pocket, which makes it difficult to assess the general validity of the model. IBMX, scoring rather poorly, also did not inhibit GRK2, but we did not test additional negative controls.
A screen of the Fine Chemicals Directory based on an acceptable GRK2 score (<-30) with similar or poorer cAPK scores and with a good fit into the adenine binding pocket of GRK2 identified one (already known) GRK2 inhibitor, trifluoperazine (Table 2A) . Furthermore, the cPKA inhibitor H8 scored well and was shown here to inhibit GKR2 weakly (Table 2B ). Other compounds, even though scoring high, failed to inhibit GRK2 at 100 μM. This result demonstrates problems incurred with the screening of chemical libraries containing structures to which a single conformation has been assigned, docked to a homology model. Errors may also occur in our homology model of GRK2. Even though the model is adequate in identifying the ATP binding site, there may be errors due to the omission of amino acids in the model of GRK2. For example, amino acids in GRK2 corresponding to several small gaps in cAPK were omitted for the construction of the model. This omission may lead to a certain distortion of the binding sites of inhibitors, thus limiting the value of the homology model. Nevertheless, we showed that most of the known inhibitors docked into the ATP binding pocket. Thus, homology model and docking showed limited utility in discovering new chemical entities as GRK2 inhibitors, but they might be useful in guiding the further design of known lead compounds.
To extend our study to structurally distinct potential kinase inhibitors not contained in the Fine Chemicals Directory used, we tested suramin, a compound previously shown to inhibit protein kinase C 39 and, very weakly, cAPK 40 . Suramin was docked into the GRK2 model and attained a high GRK2 score with a favorable fit into the central cleft ( Figure 2C [static image]), in preference to cAPK. Even though suramin is a hexasulfonic acid, its negative charges are separated by an extensive lipophilic middle portion that can be accommodated in the central cleft of GRK2. When tested in the rhodopsin phosphorylation assay, suramin was indeed shown to inhibit GRK2 in a competitive manner in regard to ATP (Figure 5) . The pA 2 value of 6.39 (competing with ATP) reveals low micromolar affinity for the ATP binding site. Further, the considerably less favorable score for suramin docking into cAPK correlated with its reported lower inhibitory potency at cAPK 40 . The differences between docking of suramin to GRK2 and cAPK may be related to their different biochemical mechanisms: whereas cAPK commonly inserts a single phosphate onto Ser or Thr contained in a consensus site 28 , GRK2 catalyzes the addition of multiple phosphates 4 . Thus, the sulfonated end of the suramin moiety docked inside the central cleft might stabilize binding to the enzyme in the same fashion as previously introduced Even though suramin is known to enter cells by endocytosis 41 , inhibitors with no or less negative charges are desirable for cell permeability. One of the sulfonated ends of suramin extended out of the central cleft of GRK2, suggesting that it does not contribute to the binding (Figure 2c [static image] ). Therefore, we tested NF520, one half of the suramin molecule ( Table 3) . Indeed, NF520 was shown weakly to inhibit GRK2 (Table  3) . Furthermore, the docking of suramin into our homology model of GRK2 suggests that compounds with a reduced number of sulfonic acid moieties but similar lipophilic aromatic residues might inhibit GRK2. We therefore tested compounds NF062 and NF503 ( Table  3 ). The number of sulfonic acid groups can be reduced without loss of affinity. The disulfonic acid analogue NF062 (the negative charges are again separated by lipophilic aromatic residues as in suramin) and NF503, a zwitterionic compound, inhibited GRK2, with lower IC50 values than suramin ( Table 3) .
Whereas docking and subsequent screening of a chemical database showed a poor success rate, probably because of a simplified homology model of GRK2, we show here that the GRK2 homology model was useful in a first evaluation of putative inhibitors (suramin analogues) that dock into the ATP binding site of GRK2. Our results establish the suramin moiety as a promising lead in the design of GRK2 inhibitors that can penetrate the cell membrane. Because a large number of suramin analogues are available, a combination of selecting candidates by docking and biochemical testing might prove suitable for finding highly potent GRK2 inhibitors.
